Safety and Tolerability of Controlled-release Oxycodone on Postoperative Pain in Oncologic Head and Neck Surgery
Safety and Tolerability of Controlled-release Oxycodone on Postoperative Pain in Oncologic Head and Neck Surgery
The hypothesis of this study is that controlled release oxycodone can be safe and well
 tolerated for the control of postoperative pain in surgery for head and neck cancer. The
 primary objective is to study the safety and the incidence and severity of adverse effects,
 and the secondary objective is to evaluate the analgesic efficacy and identify the frequency
 of use of rescue medication and the prescribing physician's opinion about the quality of
 postoperative analgesia with oxycodone controlled release in oncologic surgery of the head
 and neck.
Phase IV clinical trial, observational, prospective, open approved by the Research Ethics
 Committee of the National Cancer Institute José Alencar Gomes da Silva - INCA, Brazil (no.
 10/2010). The Instrument of Consent is signed by all patients.

 Eighty-three patients will be included. Ages between 18 and 70 years both genders, 2 and 3
 American Society of Anesthesiologists physical status, which present moderate to severe pain
 source postoperative surgical oncology, head and neck, medium and large, elective,
 non-emergency, able to swallow tablets whole (not chewed, broken or crushed) in the immediate
 postoperative period after recovery of cognitive functions. Will be excluded pregnant or
 breastfeeding, allergic to oxycodone and other opioids, gastrectomized or colostomized,
 asthmatics with severe organ dysfunction, with a history or suspected paralytic ileus, or a
 history psychiatric disorders, severe respiratory depression, patients who are receiving
 opioid analgesics in baseline, history of abuse of alcohol and illicit drugs, patients who
 present in plasma glutamic oxaloacetic transaminase above 48 U / l (men) and 40 U / I (women)
 and / or glutamic pyruvic transaminase above 53 U / l (men) and 40 U / I (women) and patients
 who present plasma creatinine above 1.7 mg / dl and / or urea above 65 mg / dl. All patients
 will be assessed preoperatively seven to one day before surgery (visit 1) when will the
 signed consent form, proceeded to pre-anesthetic evaluation and blood will be collected for
 laboratory tests: complete blood count, β-human chorionic gonadotropin(women), glutamic
 oxaloacetic transaminase, glutamic pyruvic transaminase, creatinine and urea.

 In the immediate postoperative period (visit 2), the pain will be assessed by verbal numeric
 scale (VNS) and when pain is moderate to severe (≥ 4 EVN) and the patient is lucid and able
 to swallow, will start orally controlled-release oxycodone (Oxycontin, Zodiac
 Pharmaceuticals, Brazil) at a dose of 20 mg (tablets whole without crushing or division),
 administered by the investigator. Every 12 hours and a subsequent period of 48 hours after
 the first dose of oxycodone controlled-release, the pain will be evaluated again, and the
 occurrence and intensity of adverse events (visits 3, 4, 5 and 6 respectively 12 , 24, 36 and
 48 hours after the first dose of oxycodone). The doses of controlled-release oxycodone will
 be standardized as follows: on the first day postoperatively, 40 mg / day divided into 20 mg
 of 12 in 12 hours and in the second postoperative day, 20 mg / day divided into 10 mg of 12
 in 12 hours.

 The rescue medication will be used non opioids analgesics as paracetamol, dipyrone,
 diclofenac or tenoxicam, only after the first administration of controlled-release oxycodone
 postoperatively. During the visits described above will be annotated to rescue analgesia and
 its frequency, should it ever be used between doses of oxycodone.

 Between post-operative 7 and 13 days will be held the visit 7, which will be evaluated pain
 intensity (EVN), the occurrence and severity of adverse effects, and the investigator's
 opinion about treatment. Finally, the patient's blood will be collected to perform the same
 tests listed at visit 1, except β-human chorionic gonadotropin (women), and the study was
 terminated.

 Sample Size and Statistical Analysis

 When considering the occurrence of nausea of 25% as a safety parameter, assessed by
 literature data, the number of patients required will be 72. Taking into consideration a
 dropout of about 20% will require 86 patients in total (to an accuracy of 10%, around the
 percentage confidence interval (CI) 95%). The study of normal age variable will be conducted
 with the test Kolmogorov - Smirnov. The Friedman test is used to compare medians of pain
 intensity from visit 2 to visit 7. The Dunn test will be used for post-hoc comparisons
 (between two) of median pain intensity (p <0.001 - significant). The McNemar test for
 pairwise comparisons of proportions will be employed for comparisons of adverse events
 (visits 4, 5, 6 and 7 with respect to visit 3) (p <0.05 = significant). The remaining data
 will be presented by frequency.
Inclusion Criteria:

 -  patients on postoperative head and neck oncologic surgery

 -  2 and 3 American Society of Anesthesiologists physical status

 -  moderate to severe postoperative pain

 -  elective surgery

 -  able to swallow tablets whole (not chewed, broken or crushed) in the immediate
 postoperative period after recovery of cognitive functions.

 Exclusion Criteria:

 -  pregnant or breastfeeding

 -  allergic to oxycodone and other opioids

 -  gastrectomized or colostomized

 -  asthmatics with severe organ dysfunction

 -  history or suspected paralytic ileus

 -  history psychiatric disorders

 -  severe respiratory depression

 -  patients who are receiving opioid analgesics in baseline

 -  history of abuse of alcohol and illicit drugs

 -  plasma glutamic oxaloacetic transaminase above 48 U / l (men) and 40 U / I (women) and
 / or glutamic pyruvic transaminase above 53 U / l (men) and 40 U / I (women)

 -  plasma creatinine above 1.7 mg / dl and / or urea above 65 mg / dl

 -  emergency surgery